Merck (NYSE:MRK) recently announced promising results from its Phase 3 KEYNOTE-689 trial of KEYTRUDA, presented at the AACR Annual Meeting, which seems likely to have bolstered investor confidence, ...

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...

The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain ...

Chinese regulator grants second approval for lung cancer drug ivonescimab, which has outperformed Merck’s Keytruda in phase ...

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head ...

We recently published a list of 10 Most Profitable Blue Chip Stocks to Buy Now. In this article, we are going to take a look ...

The FDA is currently reviewing Merck’s sBLA for Keytruda in head and neck cancer, with a target action date of June 23.

Market volatility has led to compelling dividend opportunities, and Merck and Schlumberger offer great value at low PE ratios ...

With ivonescimab’s data coming solely from China, its prospects in the U.S., where Summit owns the rights, remain up in the ...

New immune data from the ongoing phase 2 trial with EVX-01 will be presented at a poster session tomorrow at the American Association for Cancer Research (AACR) Annual Meeting taking place in Chicago.

Akeso Inc. shares plunged as much as 19% in Hong Kong on Monday morning after preliminary data for its new cancer drug fell ...

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this ...